Header Logo

Connection

MICHELLE A FANALE to Antineoplastic Combined Chemotherapy Protocols

Back to Details
This is a "connection" page, showing publications MICHELLE A FANALE has written about Antineoplastic Combined Chemotherapy Protocols.
MICHELLE A FANALE
Connection Strength
2.361
Antineoplastic Combined Chemotherapy Protocols
  1. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica. 2018 09; 103(9):e416-e418.
    View in: PubMed
    Score: 0.128
  2. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood. 2018 05 10; 131(19):2120-2124.
    View in: PubMed
    Score: 0.127
  3. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477.
    View in: PubMed
    Score: 0.120
  4. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. 2016 Aug 01; 2(8):1065-9.
    View in: PubMed
    Score: 0.114
  5. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506.
    View in: PubMed
    Score: 0.113
  6. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014 Oct 01; 32(28):3137-43.
    View in: PubMed
    Score: 0.099
  7. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol. 2011 Jul; 154(2):284-6.
    View in: PubMed
    Score: 0.079
  8. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer. 2005 Oct; 6(4):354-6.
    View in: PubMed
    Score: 0.054
  9. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021 Jun; 8(6):e410-e421.
    View in: PubMed
    Score: 0.040
  10. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587.
    View in: PubMed
    Score: 0.038
  11. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. J Clin Oncol. 2020 08 01; 38(22):2519-2529.
    View in: PubMed
    Score: 0.037
  12. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma. 2020 02; 61(2):328-336.
    View in: PubMed
    Score: 0.035
  13. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019 06; 185(5):874-882.
    View in: PubMed
    Score: 0.034
  14. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol. 2019 05; 185(4):670-678.
    View in: PubMed
    Score: 0.034
  15. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019 01 19; 393(10168):229-240.
    View in: PubMed
    Score: 0.033
  16. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e609-e617.
    View in: PubMed
    Score: 0.033
  17. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica. 2019 02; 104(2):e65-e67.
    View in: PubMed
    Score: 0.033
  18. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. J Clin Oncol. 2018 10 20; 36(30):3015-3022.
    View in: PubMed
    Score: 0.033
  19. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018 06 12; 2(11):1334-1343.
    View in: PubMed
    Score: 0.032
  20. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.
    View in: PubMed
    Score: 0.032
  21. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659.
    View in: PubMed
    Score: 0.032
  22. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609.
    View in: PubMed
    Score: 0.032
  23. SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):81-90.
    View in: PubMed
    Score: 0.031
  24. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Mol Cancer Ther. 2018 03; 17(3):671-676.
    View in: PubMed
    Score: 0.031
  25. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e41-e50.
    View in: PubMed
    Score: 0.031
  26. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone? Br J Haematol. 2017 11; 179(3):488-496.
    View in: PubMed
    Score: 0.031
  27. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870.
    View in: PubMed
    Score: 0.030
  28. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood. 2017 09 14; 130(11):1375-1377.
    View in: PubMed
    Score: 0.030
  29. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist. 2017 05; 22(5):549-553.
    View in: PubMed
    Score: 0.030
  30. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017 04; 177(2):263-270.
    View in: PubMed
    Score: 0.030
  31. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531.
    View in: PubMed
    Score: 0.029
  32. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma? Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):951-958.
    View in: PubMed
    Score: 0.029
  33. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol. 2017 12; 179(5):851-854.
    View in: PubMed
    Score: 0.028
  34. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151.
    View in: PubMed
    Score: 0.028
  35. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8.
    View in: PubMed
    Score: 0.028
  36. Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):110-8.
    View in: PubMed
    Score: 0.028
  37. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016 06 10; 34(17):2020-7.
    View in: PubMed
    Score: 0.028
  38. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. 2016 05; 27(5):895-901.
    View in: PubMed
    Score: 0.027
  39. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8.
    View in: PubMed
    Score: 0.027
  40. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. 2016 11; 175(3):531-533.
    View in: PubMed
    Score: 0.027
  41. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16.
    View in: PubMed
    Score: 0.027
  42. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20.
    View in: PubMed
    Score: 0.026
  43. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.
    View in: PubMed
    Score: 0.026
  44. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun; 169(6):814-23.
    View in: PubMed
    Score: 0.026
  45. Novel treatments for T-cell lymphoma. Am Soc Clin Oncol Educ Book. 2015; e468-78.
    View in: PubMed
    Score: 0.025
  46. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8.
    View in: PubMed
    Score: 0.025
  47. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84.
    View in: PubMed
    Score: 0.025
  48. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan; 15(1):69-77.
    View in: PubMed
    Score: 0.024
  49. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013 Dec; 14(13):1348-56.
    View in: PubMed
    Score: 0.024
  50. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.
    View in: PubMed
    Score: 0.023
  51. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9.
    View in: PubMed
    Score: 0.023
  52. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23.
    View in: PubMed
    Score: 0.021
  53. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8.
    View in: PubMed
    Score: 0.021
  54. Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma. 2012 Mar; 53(3):499-502.
    View in: PubMed
    Score: 0.020
  55. A systematic literature review of clinical evidence and treatment burden in newly diagnosed high-risk pediatric patients with classical Hodgkin lymphoma. Pediatr Blood Cancer. 2024 Aug; 71(8):e31027.
    View in: PubMed
    Score: 0.012
  56. Real-World Use of Positron Emission Tomography-Computed Tomography and Reported Deauville Scores in Advanced-Stage Classic Hodgkin Lymphoma: A Community Oncology Practice Perspective. JCO Oncol Pract. 2023 10; 19(10):860-870.
    View in: PubMed
    Score: 0.012
  57. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy. Oncologist. 2023 06 02; 28(6):520-530.
    View in: PubMed
    Score: 0.011
  58. Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial. Leuk Lymphoma. 2023 05; 64(5):1017-1025.
    View in: PubMed
    Score: 0.011
  59. Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States. Clin Lymphoma Myeloma Leuk. 2023 07; 23(7):527-534.
    View in: PubMed
    Score: 0.011
  60. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol. 2023 02 01; 41(4):745-755.
    View in: PubMed
    Score: 0.011
  61. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022 03; 33(3):288-298.
    View in: PubMed
    Score: 0.010
  62. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma. 2021 01; 62(1):58-67.
    View in: PubMed
    Score: 0.009
  63. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL. Am J Manag Care. 2020 02 01; 26(2):e41-e49.
    View in: PubMed
    Score: 0.009
  64. Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee. Br J Haematol. 2019 01; 184(2):292-293.
    View in: PubMed
    Score: 0.008
  65. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758.
    View in: PubMed
    Score: 0.007
  66. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer. 2017 Apr 15; 123(8):1363-1371.
    View in: PubMed
    Score: 0.007
  67. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):333-338.
    View in: PubMed
    Score: 0.007
  68. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88.
    View in: PubMed
    Score: 0.007
  69. Deeper Insights Into Vanishing Bile Duct Syndrome in Lymphoma: A Perplexing Entity. Clin Lymphoma Myeloma Leuk. 2016 05; 16(5):e65-70.
    View in: PubMed
    Score: 0.007
  70. Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):664-670.e2.
    View in: PubMed
    Score: 0.007
  71. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82.
    View in: PubMed
    Score: 0.007
  72. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. Lancet Haematol. 2015 Apr; 2(4):e166-74.
    View in: PubMed
    Score: 0.006
  73. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8.
    View in: PubMed
    Score: 0.006
  74. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901.
    View in: PubMed
    Score: 0.006
  75. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014 Apr; 165(1):112-6.
    View in: PubMed
    Score: 0.006
  76. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013 Dec 15; 19(24):6882-90.
    View in: PubMed
    Score: 0.006
  77. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):99-105.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.